NF-κB p65在非霍奇金淋巴瘤组织中的表达及临床意义
摘要
目的探讨NF-κB p65蛋白在非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)中的表达及其与临床病理特征及预后的关系。方法用免疫组织化学的方法检测35例NHL中NF-κB p65的表达情况,并分析NF-κB p65与临床病理特征的关系及其对预后的影响。结果 35例NHL标本NF-κB p65阳性表达率为54.3%(19/35),NF-κB p65的表达与体力状况评分(ECOG)、有无B症状、国际预后指数(International Prognostic Index,IPI)评分密切相关(P <0.05)。生存分析显示NF-κB p65阳性表达者平均总生存期低于阴性表达者(P=0.016),而NF-κB p65阳性表达者平均无病生存期与阴性表达者无统计学差异(P> 0.05)。结论 NF-κB p65在NHL中表达广泛,其阳性表达提示不良预后,甚至有可能成为NHL的一个重要的不良预后指标。
引文
[1]Swerdlow SH,Campo E,Pileri SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].BLOOD,2016,127(20):2375-2390.
[2]Karin M,Cao YX,Greten FR,et al.NF-kappa B in cancer:From innocent bystander to major culprit[J].Nature Reviews Cancer,2002,2(4):301-310.
[3]Cheson BD,Leonard JP.Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma[J].NEngl J Med,2008,359(6):613-626.
[4]马肖容,徐燕,王瑾,等,254例非霍奇金淋巴瘤的临床疗效与预后分析[J].中国实验血液学杂志,2016,24(4):1044-1050.
[5]Sandur SK,Deorukhkar A,Pandey MK,et al.Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappa Bactivity[J].Int J Radiat Oncol Biol Phys,2009(2);75:534-542.
[6]Prasad S,Phromnoi K,Yadav VR,et al.Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer[J].Planta Med,2010;76(11):1044-1063.
[7]Zhang MZ,Xu-Monette,Ling L,et.al.Rel A NF-k B subunit activation as a therapeutic target in diffuse large B-cell lymphoma[J].Aging,2016,8(12):3321-3340.
[8]Wang J,Zhou M,Zhang QG,et.al.Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCLpatients[J].Oncotarget,2017,8(6):9708-9716.
[2]Karin M,Cao YX,Greten FR,et al.NF-kappa B in cancer:From innocent bystander to major culprit[J].Nature Reviews Cancer,2002,2(4):301-310.
[3]Cheson BD,Leonard JP.Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma[J].NEngl J Med,2008,359(6):613-626.
[4]马肖容,徐燕,王瑾,等,254例非霍奇金淋巴瘤的临床疗效与预后分析[J].中国实验血液学杂志,2016,24(4):1044-1050.
[5]Sandur SK,Deorukhkar A,Pandey MK,et al.Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappa Bactivity[J].Int J Radiat Oncol Biol Phys,2009(2);75:534-542.
[6]Prasad S,Phromnoi K,Yadav VR,et al.Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer[J].Planta Med,2010;76(11):1044-1063.
[7]Zhang MZ,Xu-Monette,Ling L,et.al.Rel A NF-k B subunit activation as a therapeutic target in diffuse large B-cell lymphoma[J].Aging,2016,8(12):3321-3340.
[8]Wang J,Zhou M,Zhang QG,et.al.Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCLpatients[J].Oncotarget,2017,8(6):9708-9716.